Pharma BD Deal Intelligence
Dificid was a logical bolt-on for Cubist's hospital-acute antibiotics franchise, but it never came close to blockbuster status — the deal's own contingent-value-right structure collapsed in value within six months, foreshadowing a decade of sub-$65M/year sales against an ~$0.8B price tag.
Full analysis, sources & comparables →Cubist CEO Michael Bonney: 'Optimer is a natural fit for Cubist given our co-promotion of DIFICID and focus on the acute care and hospital environments. The…
Cubist's tandem Optimer/Trius deals are framed as a deliberate consolidation of specialized hospital ID expertise — Dificid as 'the first antibacterial…
Even with Dificid in hand, Cubist faces 'hurdles in diversifying beyond flagship drug' Cubicin — Dificid uptake constrained by formulary cost barriers despite…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Cubist to acquire Optimer at $10.75/share + CVR up to $5/share (total up to $801M fully diluted); converted existing Dificid co-promote into outright ownership of CDAD franchise.
Dificid was a logical bolt-on for Cubist's hospital-acute antibiotics franchise, but it never came close to blockbuster status — the deal's own contingent-value-right structure collapsed in value within six months, foreshadowing a decade of sub-$65M/year sales against an ~$0.8B price tag.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cubist Pharmaceuticals, Inc. / Optimer Pharmaceuticals, Inc. (this deal) | 2013 | $801M | 45 |
| Cubist Pharmaceuticals, Inc. / Calixa Therapeutics, Inc. | 2009 | $402M | 52 |
| Cubist Pharmaceuticals, Inc. / Adolor Corporation | 2011 | $415M | 49 |
| Cubist Pharmaceuticals, Inc. / Trius Therapeutics Inc. | 2013 | $707M | 44 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
← Browse all deals · How we score deals
More: 2013 deals · Cubist Pharmaceuticals, Inc. deals · Infectious Disease deals